

H.R. 3884, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2023

As reported by the House Committee on Energy and Commerce on August 25, 2023

By Fiscal Year, Millions of Dollars	2024	2024-2028	2024-2033
Direct Spending (Outlays)	0	0	0
Revenues	0	0	0
Increase or Decrease (-) in the Deficit	0	0	0
Spending Subject to Appropriation (Outlays)	5	37	41
Increases <i>net direct spending</i> in any of the four consecutive 10-year periods beginning in 2034?	No	Statutory pay-as-you-go procedures	apply? No
		Mandate Effects	
Increases <i>on-budget deficits</i> in any of the four consecutive 10-year periods beginning in 2034?	No	Contains intergovernmental mandate	e? No
		Contains private-sector mandate?	No

H.R. 3884 would authorize the appropriation of \$8 million each year from 2024 through 2028 for the Centers for Disease Control and Prevention and the Health Resources and Services Administration to conduct research, surveillance, prevention, and treatment of sickle cell disease and related blood disorders. (In 2023, \$4 million was allocated for these purposes.) Based on historical spending patterns for those activities and assuming the appropriation of the authorized amounts, CBO estimates that implementing the bill would cost \$37 million over the 2024-2028 period and \$4 million after 2028.

The costs of the legislation, detailed in Table 1, fall within budget function 550 (health).

Table 1. Estimated Increases in Spending Subject to Appropriation Under H.R. 3884									
	By Fiscal Year, Millions of Dollars								
	2024	2025	2026	2027	2028	2024-2028			
Authorization	8	8	8	8	8	41			
Estimated Outlays	5	8	8	8	8	37			



The CBO staff contact for this estimate is Julianna Mack. The estimate was reviewed by Sarah Masi, Senior Adviser for Budget Analysis.

Phil h

Phillip L. Swagel Director, Congressional Budget Office